ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: L06

Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards

Mark C. Genovese1, Kenneth C. Kalunian2, David Walker3, Jacques-Eric Gottenberg4, Kurt de Vlam5, Neelufar Mozaffarian6, Beatrix Bartok6, Franziska Matzkies6, Jie Gao6, Ying Guo6, Chantal Tasset7, John S. Sundy6 and Tsutomu Takeuchi8, 1Division of Immunology & Rheumatology, Stanford University, Stanford, CA, 2Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 3Northumbria Healthcare, United Kingdom, United Kingdom, 4Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 5Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 6Gilead Sciences, Inc., Foster City, CA, 7Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, 8Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Date of first publication: October 4, 2018

Keywords: DMARDs, Janus kinase (JAK), Late-Breaking 2018, methotrexate (MTX), rheumatoid arthritis (RA) and rheumatoid arthritis, treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, October 23, 2018

Session Title: Late-Breaking Abstract Poster Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient response to MTX, warranting further evaluation in phase 3.

Methods: In this global, phase 3 study (ClinicalTrials.gov Identifier: NCT02873936), pts with moderately-to-severely active RA and an inadequate response or intolerance to 1 or more prior biologic DMARDs (bDMARDs), were randomized 1:1:1 to once daily FIL 200 mg, 100 mg, or placebo (PBO) for 24 weeks; pts were required to continue stable conventional synthetic DMARDs. The primary endpoint was the proportion of subjects who achieved an ACR20 response at Week (Wk) 12.

Results: Baseline characteristics of the 448 pts randomized and treated with the study drug (FIL 200 mg, n=147; FIL 100 mg, n=153; and PBO, n=148) included: 80.4% female; 23.4% ≥ 3 prior bDMARDs; 56 yrs mean age; 12.4 yrs RA disease duration; 27 of 68 tender joint count; 17 of 66 swollen joint count; and 5.9 DAS28(CRP). At Wk 12, an ACR20 response was achieved by more pts receiving FIL 200 mg or 100 mg than PBO (66.0, 57.5 and 31.1%, respectively; both p<0.001) (Table 1). The reduction from baseline in HAQ-Disability Index (HAQ-DI) at Wk 12 was greater in the FIL 200 mg and 100 mg groups compared to the PBO group (-0.55 and -0.48 vs -0.23, respectively; both p<0.001). Other key secondary endpoints, including SF-36 and FACIT-Fatigue, were also met at both FIL doses (Table 1).

Adverse event (AE) rates were similar for FIL 200 mg, FIL 100 mg and PBO groups (69.4% and 63.4% vs 67.6%, respectively) as were rates of serious AEs (4.1%, 5.2% and 3.4%, respectively) (Table 2). There were 4 cases of uncomplicated herpes zoster (2 in each FIL group). There was one non-serious AE of retinal vein occlusion in the FIL 200 mg group; no other venous thrombotic events were reported. Two adjudicated MACE were reported: subarachnoid hemorrhage in the PBO group and myocardial ischemia in the FIL 100 mg group. There were no cases of opportunistic infection/active TB, malignancy, GI perforation or death.  

Conclusion: In this phase 3 study of pts with highly active RA and prior inadequate response/intolerance to bDMARDs, treatment with FIL over a 24-week period was associated with significant improvement in the signs and symptoms of RA, with a safety profile consistent with Phase 2 data. FIL may provide a novel treatment option for pts who continue to have active RA despite prior biologic therapies.

This study was sponsored by Gilead Sciences, Inc.


Disclosure: M. C. Genovese, Gilead, 2, 5,Galapagos, 2, 5,AbbVie Inc., 2, 5,Lilly, 2, 5,Pfizer, Inc., 2, 5; K. C. Kalunian, Gilead, 2; D. Walker, None; J. E. Gottenberg, None; K. de Vlam, None; N. Mozaffarian, Gilead Sciences, 1, 3; B. Bartok, Gilead Sciences, 1, 3; F. Matzkies, Gilead Sciences, 1, 3; J. Gao, Gilead Sciences, 1, 3; Y. Guo, Gilead Sciences, 1, 3; C. Tasset, Galapagos NV, 1; J. S. Sundy, Gilead Sciences, 1, 3; T. Takeuchi, None.

To cite this abstract in AMA style:

Genovese MC, Kalunian KC, Walker D, Gottenberg JE, de Vlam K, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, Takeuchi T. Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/safety-and-efficacy-of-filgotinib-in-a-phase-3-trial-of-patients-with-active-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-biologic-dmards/. Accessed December 11, 2019.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-filgotinib-in-a-phase-3-trial-of-patients-with-active-rheumatoid-arthritis-and-inadequate-response-or-intolerance-to-biologic-dmards/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.